EF Hutton puts Kaufempfehlung for Reviva Pharmaceuticals-Aktien from Investing.com

EF Hutton has established the Beobachtung of Reviva Pharmaceuticals (NASDAQ: RVPH) and issued a purchase note with a price of US$15.00.

The company is optimistic about the potential of Reviva’s drug candidate Brilaroxazine to treat schizophrenia worldwide.

Following positive results from Unternehmen’s Phase 3 Study Plant, a Zulassungsantrag (NDA) will be completed in the quarter of 2026.

The analyst of EF Hutton has discovered that the brilaroxazin may be on the treatment of other people with bipolar disorder, depression and various other diseases, psoriasis, idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) suffers, which may help. The ability of the ability to increase Brilaroxazin, provides a greater effect on the functioning of the Firm at.

In his Finanzmodellen EF Hutton has developed and validated a 70% probability of success for the schizophrenia indication as a central element in the assessment of Reviva Pharmaceuticals. If the model is used in a model that is used at 30%, there is a potential risk and a concern about its use.

The company that was formed, the company that Reviva Pharmaceuticals possibly did with Kapital, was in the predicted Aktienanzahl a single entity. EF Hutton’s Bevaluation is based on a combination of the free cash flow to the entity (FCFF), the winnings from operations (dEPS) and sum-of-the-parts (SOP) models.

In other active studies Reviva Pharmaceuticals has positively evaluated the Phase 3 RECOVER trial of brilaroxazine for the treatment of schizophrenia, it was reported that all primary and secondary endpoints were achieved.

The fact that American and European patents for Brilaroxazines exist was a protection of the own geiste properties. HC Wainwright has undergone a revival of a Kaufempfehlung, which has withstood its 12-month course for a revival of 20 to 14 US dollars after a capital increase of one of the other countries.

Reviva plant, Brilaroxazin, is used for other neuropsychiatric indications and has been granted orphan drug status by the US-FDA for the best pulmonary medicine. If you use a European patent for your drug, the jurisdiction for the treatment of alveoli hypertonia and pulmonary artery hypertonia is erweitert.

The companies can close a capital increase, at a cost of 1.9 million capital stocks will be placed. The FDA has revived a Phase-3 RECOVER-2 study for Brilaroxazine, a potential treatment for schizophrenia, and the study will begin in due course.

InvestingPro Insights

Während Reviva Pharmaceuticals (NASDAQ: RVPH) is on track for better financing for Brilaroxazine, with investors and analysts noting the weak financial and market performance of its companies. Laut InvestingPro-Daten have revived a market cap of US$42.36 million, the growth of the companies in the pharmaceutical industry has become light. The profit from the optimistic results of the candidate drugs was at the short-term profit ratio (KGV) at -0.98, and the Einschatzung der investors over the recovery potential broader mirror.

While the investment pro investment for Reviva Pharmaceuticals as one of the more Barmittel debt in the Bilanz company was based on a solid financial basis, it was a solid financial basis. Other analysts have consulted their profit forecasts for the coming period after the correction, but there were some results in the financial outlook of the Unternehmens signaling. The fact that this party took place, when the revival led a large profit margin and did not exercise a dividend, was for a single orientation that was relevant to someone.

For investors, who give the financial and market performance of Reviva Pharmaceuticals a chance, InvestingPro also offers an overview and knowledge, with 12 InvestingPro tips on its platform. These switches are based on the young performance of the company, which shows a beach yield of 32.07% in the month, but also to the recovery, the companies have been replaced, which compares the course performance in the years. For a comprehensive analysis, you can consult interesting detailed InvestingPro solutions for Reviva Pharmaceuticals.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.